What Autobio Diagnostics does

Autobio Diagnostics (郑州安图生物工程股份有限公司, ticker: 603658) is a publicly listed Chinese in vitro diagnostics (IVD) company headquartered in Zhengzhou, Henan Province, founded in 1998 and listed on the Shanghai Stock Exchange Main Board in September 2016 — the first IVD R&D and manufacturing enterprise to list on the SSE Main Board. The company designs, manufactures, and sells diagnostic instruments, reagents, and integrated laboratory automation systems spanning immunoassay (magnetic particle chemiluminescence), microbiology (mass spectrometry, identification, susceptibility), biochemistry, molecular diagnostics (PCR), coagulation, and next-generation sequencing. It also offers custom laboratory solutions including intelligent laboratory construction, lean management consulting (AutoLean), and quality control software.

The technology stack is anchored by a proprietary magnetic particle chemiluminescence platform with 225+ detection items and a localized microbial mass spectrometry database covering 5,000+ species, supplemented by purpose-built analyzers such as the AutoLumo A9000 (up to 3,200 tests/hour), AutoChem B2000 (2,000 tests/hour), Autof T series mass spectrometers, AutoMolec 3000 PCR systems, and the Autolas X-1 automated assembly line. R&D strength is unusually high for the industry: 2,000+ R&D personnel (30% of total workforce), 18.16% R&D-to-revenue ratio, 6 R&D centers across China and North America, 1,040+ product registration certificates, 2,000+ patents, and 368 EU CE certifications for immunodiagnostic products.

Autobio's revenue model is a B2B enterprise razor/blade model: hardware (analyzers, assembly lines) is sold or placed with hospitals and clinical laboratories, while recurring consumables (reagents, test kits) generate the ongoing revenue stream, supplemented by laboratory services and international distribution. The company sells directly to medical laboratories, hospitals, and clinical testing centers across all 30 Chinese provincial administrative regions and through distribution networks in 110+ countries, with wholly-owned subsidiaries in Indonesia and a reference laboratory in Hungary as of 2026. FY2025 revenue was 4.226 billion CNY with net profit of 1.068 billion CNY (~25% net margin), placing the company among the top-tier Chinese IVD players by scale.

Name

Autobio Diagnostics

Legal name

郑州安图生物工程股份有限公司 (Zhengzhou Autobio Bioengineering Co., Ltd.)

Website

https://autobio.com.cn

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Autobio Diagnostics is a publicly listed Chinese in vitro diagnostics company that develops, manufactures, and sells immunoassay, microbiology, biochemistry, molecular, coagulation, and sequencing instruments, reagents, and automated laboratory systems to hospital laboratories and clinical testing centers across China and 110+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Zhengzhou

HQ country

China

HQ region

Asia

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. IVD Reagent Sales: Sale of in vitro diagnostic reagents covering immunodiagnostics, microbiology, biochemistry, molecular diagnostics, and coagulation testing. Products include 1040+ product registrations (as of 2025), including 515 immunodiagnostic registration certificates and 201 biochemical product registrations.
2. Diagnostic Instrument Sales: Manufacturing and sale of automated diagnostic instruments including chemiluminescence analyzers, biochemical analyzers, mass spectrometry systems, molecular diagnostic systems, coagulation analyzers, and automated laboratory assembly lines.
3. Laboratory Solutions and Services: Complete laboratory solutions including intelligent medical laboratory construction, AutoLean lean management consulting services, laboratory quality control services, and laboratory building services.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Autobio Diagnostics develops, manufactures, and sells in-vitro diagnostic (IVD) products including clinical chemistry reagents, immunoassay reagents, microbiology reagents, automated diagnostic analyzers, and laboratory automation systems. The portfolio is targeted at hospital laboratories, independent clinical labs, and other healthcare providers performing routine and specialty diagnostic testing. Its reagent menu spans immunoassay, microbiology, and clinical chemistry applications, complemented by proprietary instruments and total laboratory automation (TLA) platforms that integrate analyzers, reagents, and middleware into unified workflows.

Product overview

安图生物是一家专注于体外诊断试剂和仪器的研发、制造、整合及服务的公司，产品涵盖免疫、微生物、生化、分子、凝血等检测领域，并延伸至测序、质谱、精准检测和智慧化医学实验室等领域。主要产品包括：流水线产品系列（Autolas B-1 Star、Autolas X-1、Autolas A-1、Autolas B-1系列），免疫产品系列（AutoLumo A9000、A6000、A2000 Plus、A1800、S900、AutoFlex 300），生化产品系列（AutoChem B2000、AutoChem B800、TBA-FX8、TBA-2000FR、TBA-120FR），微生物产品系列（Autof T系列质谱、AutoStreak S1800、BC120 Plus、BC120、AutoMic-i600、AutowoMO W500、GLP-F300），分子产品系列（AutoMolec 3000、AutoMolec 1600），凝血产品系列（AutoCimo C6000、Ci-330、Ci-310、Ci-120x），精准检测产品系列（Sikun系列基因测序仪、AISPre 3200、Automs TQ6000、Auto Master、AutoNaseq系列纳米孔测序仪），以及POCT产品系列（呼吸道抗原检测试剂盒等）。公司还提供AutoLean®精益管理解决方案、医学实验室智能化解决方案、实验室质量控制服务等配套服务，为医学实验室提供全面的产品解决方案和整体服务。

Differentiator

Problem solved

Functional benefit

Brands

• AutoLumo: Fully automated chemiluminescence immunoassay analyzer series
• AutoChem
• Autolas
• Autof
• AutoMolec
• AutoMic-i600
• AutoCimo
• AutoLean
• BiQAS
• Sikun
• AutoNaseq
• Automs TQ6000

Products and services

• Immunoassay diagnostic reagents Clinical immunoassay reagent kits (chemiluminescence and related immunoassay formats) used on Autobio automated immunoassay analyzers to detect and quantify analytes for clinical diagnostics. Targeted at hospital laboratories, independent clinical labs, and other healthcare providers performing routine and specialty immunoassay testing.
• Microbiology diagnostic reagents Reagents and consumables for microbial culture, identification, and antimicrobial susceptibility testing used with Autobio microbiology instruments in clinical microbiology laboratories. Targeted at hospital microbiology labs and reference laboratories performing infectious disease diagnostics.
• Clinical chemistry reagents Reagent kits for clinical chemistry analytes (e.g., liver, renal, lipid, electrolyte, and other routine chemistry panels) run on Autobio clinical chemistry analyzers. Targeted at hospital and clinical laboratories performing high-volume routine chemistry testing.
• Automated immunoassay analyzers Automated chemiluminescence immunoassay analyzer instruments that run Autobio immunoassay reagent kits for clinical diagnostics. Sold to hospital laboratories, independent clinical laboratories, and other healthcare providers; instrument placement drives recurring reagent consumption.
• Microbiology identification and susceptibility analyzers Automated instruments for microbial identification and antimicrobial susceptibility testing used with Autobio microbiology reagents in clinical microbiology laboratories. Targeted at hospital and reference microbiology laboratories.
• Total Laboratory Automation (TLA) systems Integrated laboratory automation track systems that connect pre-analytical, analytical (analyzers), and post-analytical stages into a unified workflow, paired with middleware for laboratory information management. Sold to hospital and reference laboratories seeking consolidated, high-throughput testing operations.

Quantifiable outcome

• 8000 tests/hour biochemical detection speed with Autolas X-1 Series
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and legacy.

• 迈克赛德 (Maccure)coreStrategic or Co-development Partner · 1 January 2025Strategic cooperation in urine analysis field achieving technology, product and market synergies. Expands Autobio's diagnostic offerings in the urinalysis segment.
• 郑州绿科生物工程有限公司 (Zhengzhou Lvke Bio-Engineering)legacyStrategic or Co-development Partner · 1 January 2024Acquired in 2003 to establish automated microbiology plate production line and enter reagent scale production stage.
• 希肯医疗 (Xikan Medical)coreStrategic or Co-development Partner · 1 January 2021Strategic cooperation in coagulation testing field. Autobio entered the coagulation detection market through this partnership, combining Xikan Medical's expertise with Autobio's comprehensive IVD portfolio.
• 佳能 (Canon)coreChannel Partner/ Reseller/ Distributor · 1 January 2017Strategic integration to obtain Canon biochemical analyzer China distribution rights, expanding Autobio's biochemical product portfolio and market reach.
• 北京百奥泰康生物技术有限公司 (Beijing BioBAY Bio-Tech)coreStrategic or Co-development Partner · 1 January 2017Acquisition to build biochemical product line. Established Autobio's presence in biochemical reagent market through strategic consolidation.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Shenzhen Mindray Bio-Medical Electronics: China's largest medical-device/IVD conglomerate with overlapping chemiluminescence, biochemistry, hematology and lab-automation lines; competes head-to-head with Autobio across most PRC hospital tenders.
• bioMérieux: Global microbiology and immunoassay leader; directly comparable to Autobio's MALDI-TOF Autof T and VITEK-style antimicrobial-susceptibility analyzers in the microbiology segment.
• Maccura Biotechnology: Domestic IVD peer with overlapping clinical chemistry, immunoassay and rapid-test product lines; recently partnered with Autobio in urinalysis, indicative of directly competitive Chinese IVD market overlap.
• Shenzhen New Industries Biomedical Engineering (Snibe): China's leading chemiluminescence immunoassay specialist; competes directly with Autobio's AutoLumo platform in immunoassay menu and installed-base share.
• Bruker: MALDI-TOF mass spectrometry incumbent (Biotyper) for clinical microbiology identification; directly comparable to Autobio's Autof T series targeting the same clinical MALDI workflow.

Regional players

• KingMed Diagnostics: China's largest independent clinical reference laboratory network; complement to, and partial competitor with, Autobio's Hungarian reference lab and regional lab-center strategy.

Broad incumbents

• Roche Diagnostics: Global IVD market leader across immunoassay, biochemistry, molecular and tissue diagnostics; sets the upper-bound performance and pricing benchmark Autobio's chemiluminescence competes against.
• Siemens Healthineers: Broad IVD and lab-automation incumbent (Atellica, ADVIA Centaur); competes in Chinese mid-to-large hospital accounts and in lab-automation-line deals where Autobio's Autolas series is positioned.
• Abbott Diagnostics: Global IVD incumbent with strong chemiluminescence and rapid-test portfolios; competes with Autobio in Chinese VBP contexts and in CE-marked international markets.

Emerging players

• Yhlo (Shenzhen Yhlo Biotech): Chinese autoimmune and specialty-immunoassay developer; competes with Autobio's autoimmune antibody detection product series launched in 2024.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autobio Diagnostics